E. Glowienka

发表

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%

N. Freemantle, P. Guyot, G. Gullo, 2022, Therapeutic advances in medical oncology.

Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.

P. Guyot, F. Wilson, C. Smare, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.